Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

65406 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-01-31

Study Completion Date

2020-02-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Examine the risk of cardiovascular events (cardiac arrhythmia or myocardial ischemia) or all-cause mortality in Chronic Obstructive Pulmonary Disease (COPD) patients who are new users of Olodaterol or other LABAs available for the treatment of COPD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Drug Utilization Study for Olodaterol

NCT03030638

Pulmonary Disease, Chronic Obstructive

COMPLETED

Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events

NCT02096731

Pulmonary Disease, Chronic Obstructive

COMPLETED

Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers

NCT02030535

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE2

Preventing Adverse Cardiac Events in COPD

NCT03917914

Chronic Obstructive Pulmonary Disease Cardiovascular Diseases

COMPLETED PHASE3

Cardiovascular Function in COPD Patients

NCT03055988

Pulmonary Disease, Chronic Obstructive

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Purpose:

Time Perspective:

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

new users of Olodaterol

COPD patients using Olodaterol for the first time

No interventions assigned to this group

new users of other LABAs

COPD patients using other long-acting beta2 agonists for the first time

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* COPD diagnosis
* aged 40 years or older (to minimise the likelihood of including individuals who have asthma only)
* New user of olodaterol or a new user of indacaterol, salmeterol, or formoterol (not in fixed-dose combination with an inhaled corticosteroid) and have no dispensing of any LABA in the 6 months before the index date
* at least 1 year of enrolment in the electronic database before their first LABA dispensing (defined as the index LABA)
* Complete data on sex